{"id":"https://openalex.org/W4282053957","doi":"https://doi.org/10.1200/jco.22.00369","title":"Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program","display_name":"Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program","publication_year":2022,"publication_date":"2022-06-04","ids":{"openalex":"https://openalex.org/W4282053957","doi":"https://doi.org/10.1200/jco.22.00369","pmid":"https://pubmed.ncbi.nlm.nih.gov/35658474","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10166352"},"language":"en","primary_location":{"id":"doi:10.1200/jco.22.00369","doi":"https://doi.org/10.1200/jco.22.00369","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.22.00369","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00369?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00369?role=tab","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090621600","display_name":"Abdul Rafeh Naqash","orcid":"https://orcid.org/0000-0001-7622-720X","observed_orcids":["https://orcid.org/0000-0001-7622-720X"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I2803024077","display_name":"University of Oklahoma Medical Center","ror":"https://ror.org/01w8whh21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2803024077"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4390039380","display_name":"OU Health Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039271","https://openalex.org/I4390039380"]},{"id":"https://openalex.org/I8692664","display_name":"University of Oklahoma","ror":"https://ror.org/02aqsxs83","country_code":"US","type":"education","lineage":["https://openalex.org/I8692664"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdul Rafeh Naqash","raw_affiliation_strings":["Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD","Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK"],"raw_orcid":"https://orcid.org/0000-0001-7622-720X","affiliations":[{"raw_affiliation_string":"Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK","institution_ids":["https://openalex.org/I2803024077","https://openalex.org/I4390039380","https://openalex.org/I8692664"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071103539","display_name":"Melissa Moey","orcid":"https://orcid.org/0000-0002-8117-0487","observed_orcids":["https://orcid.org/0000-0002-8117-0487"]},"institutions":[{"id":"https://openalex.org/I1341135885","display_name":"Vidant Medical Center","ror":"https://ror.org/00bxj7497","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1341135885","https://openalex.org/I2799567697"]},{"id":"https://openalex.org/I186335123","display_name":"East Carolina University","ror":"https://ror.org/01vx35703","country_code":"US","type":"education","lineage":["https://openalex.org/I186335123"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Y.Y. Moey","raw_affiliation_strings":["Department of Cardiovascular Sciences, Vidant Medical Center/East Carolina University, Greenville, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cardiovascular Sciences, Vidant Medical Center/East Carolina University, Greenville, NC","institution_ids":["https://openalex.org/I1341135885","https://openalex.org/I186335123"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080277079","display_name":"Xiao-Wei Cherie Tan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]},{"id":"https://openalex.org/I4390039317","display_name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","ror":"https://ror.org/01vft3j45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I14285509","https://openalex.org/I4390039317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiao-Wei Cherie Tan","raw_affiliation_strings":["Department of Hematology-Oncology, The University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD","University of Maryland, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology-Oncology, The University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD","institution_ids":["https://openalex.org/I126744593","https://openalex.org/I4390039317"]},{"raw_affiliation_string":"University of Maryland, Baltimore, MD","institution_ids":["https://openalex.org/I126744593"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084107538","display_name":"Mehak Masood Laharwal","orcid":"https://orcid.org/0000-0003-3898-1927","observed_orcids":["https://orcid.org/0000-0003-3898-1927"]},"institutions":[{"id":"https://openalex.org/I1283092701","display_name":"Saint Barnabas Medical Center","ror":"https://ror.org/024esvk12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1283092701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehak Laharwal","raw_affiliation_strings":["Internal Medicine, Barnabas Health, Livingston, NJ"],"raw_orcid":"https://orcid.org/0000-0003-3898-1927","affiliations":[{"raw_affiliation_string":"Internal Medicine, Barnabas Health, Livingston, NJ","institution_ids":["https://openalex.org/I1283092701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064511804","display_name":"Vanessa Hill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154570441","display_name":"University of California, Santa Barbara","ror":"https://ror.org/02t274463","country_code":"US","type":"education","lineage":["https://openalex.org/I154570441"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vanessa Hill","raw_affiliation_strings":["Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA","institution_ids":["https://openalex.org/I154570441"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034846395","display_name":"Nagabhishek Moka","orcid":"https://orcid.org/0000-0002-4906-0106","observed_orcids":["https://orcid.org/0000-0002-4906-0106"]},"institutions":[{"id":"https://openalex.org/I4210106462","display_name":"Appalachian Regional Healthcare","ror":"https://ror.org/01gf20981","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210106462"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nagabhishek Moka","raw_affiliation_strings":["Appalachian Regional Healthcare Cancer Center, Hazard, KY","Appalachian Regional Healthcare Cancer Center, Hazard, KY 3450"],"raw_orcid":"https://orcid.org/0000-0002-4906-0106","affiliations":[{"raw_affiliation_string":"Appalachian Regional Healthcare Cancer Center, Hazard, KY","institution_ids":["https://openalex.org/I4210106462"]},{"raw_affiliation_string":"Appalachian Regional Healthcare Cancer Center, Hazard, KY 3450","institution_ids":["https://openalex.org/I4210106462"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077629580","display_name":"Shanda R. Finnigan","orcid":"https://orcid.org/0000-0002-0555-8965","observed_orcids":["https://orcid.org/0000-0002-0555-8965"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shanda Finnigan","raw_affiliation_strings":["Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD"],"raw_orcid":"https://orcid.org/0000-0002-0555-8965","affiliations":[{"raw_affiliation_string":"Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109848122","display_name":"James H. Murray","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087566","display_name":"Technical Resources International (United States)","ror":"https://ror.org/004fmj330","country_code":"US","type":"company","lineage":["https://openalex.org/I4210087566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Murray","raw_affiliation_strings":["Technical Resources International, Inc, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Technical Resources International, Inc, Bethesda, MD","institution_ids":["https://openalex.org/I4210087566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas B. Johnson","raw_affiliation_strings":["Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":"https://orcid.org/0000-0002-6390-773X","affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019401898","display_name":"Javid J. Moslehi","orcid":"https://orcid.org/0000-0001-5443-4312","observed_orcids":["https://orcid.org/0000-0001-5443-4312"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Javid J. Moslehi","raw_affiliation_strings":["Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022594161","display_name":"Elad Sharon","orcid":"https://orcid.org/0000-0002-0044-9719","observed_orcids":["https://orcid.org/0000-0002-0044-9719"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Elad Sharon","raw_affiliation_strings":["Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD"],"raw_orcid":"https://orcid.org/0000-0002-0044-9719","affiliations":[{"raw_affiliation_string":"Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":16,"corresponding_author_ids":["https://openalex.org/A5022594161"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"],"apc_list":null,"apc_paid":null,"fwci":6.9014,"has_fulltext":true,"cited_by_count":87,"citation_normalized_percentile":{"value":0.98183402,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"40","issue":"29","first_page":"3439","last_page":"3452"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11638","display_name":"Cardiac tumors and thrombi","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8849999904632568},{"id":"https://openalex.org/keywords/major-adverse-cardiac-events","display_name":"major adverse cardiac events","score":0.9599999785423279},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8600000143051147},{"id":"https://openalex.org/keywords/myocarditis","display_name":"myocarditis","score":0.8999999761581421},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8009999990463257},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immune-related-cardiotoxicity","display_name":"immune-related cardiotoxicity","score":0.7369999885559082},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.5519999861717224},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5889999866485596},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.6899999976158142},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.5379999876022339},{"id":"https://openalex.org/keywords/pooled-analysis-of-clinical-trials","display_name":"pooled analysis of clinical trials","score":0.6930000185966492},{"id":"https://openalex.org/keywords/incidence-and-mortality","display_name":"incidence and mortality","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9375091791152954},{"id":"https://openalex.org/C2780739214","wikidata":"https://www.wikidata.org/wiki/Q6723023","display_name":"Mace","level":4,"score":0.8560259342193604},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6506274938583374},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6310162544250488},{"id":"https://openalex.org/C2780875844","wikidata":"https://www.wikidata.org/wiki/Q186235","display_name":"Myocarditis","level":2,"score":0.5903722047805786},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5591064691543579},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47921425104141235},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45785555243492126},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.43725624680519104},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.09570568799972534},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C45393284","wikidata":"https://www.wikidata.org/wiki/Q191012","display_name":"Conventional PCI","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009205","descriptor_name":"Myocarditis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D054547","descriptor_name":"National Cancer Institute (U.S.)","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1200/jco.22.00369","doi":"https://doi.org/10.1200/jco.22.00369","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.22.00369","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00369?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10166352","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10166352","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10166352/pdf/jco-40-3439.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Clin Oncol","raw_type":"Text"},{"id":"pmid:35658474","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35658474","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Journal Article"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt4zs6h3vb","doi":null,"is_oa":false,"landing_page_url":"https://escholarship.org/uc/item/4zs6h3vb","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Clinical Oncology, vol 40, iss 29","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1200/jco.22.00369","doi":"https://doi.org/10.1200/jco.22.00369","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.22.00369","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00369?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G6907566170","display_name":"Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension","funder_award_id":"R01HL141466","funder_id":"https://openalex.org/F4320337338","funder_display_name":"National Heart, Lung, and Blood Institute"},{"id":"https://openalex.org/G9000897707","display_name":"Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis","funder_award_id":"R01HL156021","funder_id":"https://openalex.org/F4320337338","funder_display_name":"National Heart, Lung, and Blood Institute"},{"id":"https://openalex.org/G9000919000","display_name":"Long-Term Cardiovascular Sequelae of Cancer Immunotherapies","funder_award_id":"R01HL155990","funder_id":"https://openalex.org/F4320337338","funder_display_name":"National Heart, Lung, and Blood Institute"}],"funders":[{"id":"https://openalex.org/F4320306239","display_name":"Conquer Cancer Foundation","ror":"https://ror.org/027327e78"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320310179","display_name":"University of Oklahoma","ror":"https://ror.org/02aqsxs83"},{"id":"https://openalex.org/F4320333795","display_name":"Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02"},{"id":"https://openalex.org/F4320337338","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4282053957.pdf","grobid_xml":"https://content.openalex.org/works/W4282053957.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W46814359","https://openalex.org/W1973012451","https://openalex.org/W2064370814","https://openalex.org/W2140921081","https://openalex.org/W2547133566","https://openalex.org/W2771433910","https://openalex.org/W2789315292","https://openalex.org/W2793167197","https://openalex.org/W2891486030","https://openalex.org/W2901191795","https://openalex.org/W2949901067","https://openalex.org/W2950056455","https://openalex.org/W2955729565","https://openalex.org/W3002425056","https://openalex.org/W3031476671","https://openalex.org/W3034894621","https://openalex.org/W3089761109","https://openalex.org/W3112795121","https://openalex.org/W3149397307","https://openalex.org/W4214924062","https://openalex.org/W4240338964"],"related_works":["https://openalex.org/W4281654209","https://openalex.org/W3176930255","https://openalex.org/W4377102903","https://openalex.org/W3191756003","https://openalex.org/W4281778182","https://openalex.org/W4404328495","https://openalex.org/W2968221129","https://openalex.org/W3012061428","https://openalex.org/W4306254544","https://openalex.org/W7204690389"],"abstract_inverted_index":{"PURPOSE":[0],"Major":[1],"adverse":[2,15,68],"cardiac":[3,23],"events":[4,16,69],"(MACEs)":[5],"because":[6],"of":[7,22,44,62,72,120,152,165,167,184,194,204,232,246,253,269,288,299,302,308],"immune":[8],"checkpoint":[9],"inhibitors":[10],"(ICIs)":[11],"are":[12],"infrequent":[13],"immune-related":[14],"(irAEs)":[17],"that":[18],"comprise":[19],"a":[20,58,229],"spectrum":[21],"toxicities":[24],"with":[25,49,101,113,132,147,173,188,208,214,234,304,312],"variable":[26],"manifestations.":[27],"ICI-related":[28,145],"MACEs":[29,45],"can":[30],"lead":[31],"to":[32,40,260],"significant":[33],"morbidity":[34],"and":[35,46,90,282,290],"mortality,":[36],"hence":[37],"the":[38,66,73,300,305],"need":[39],"better":[41],"define":[42],"presentations":[43],"their":[47],"association":[48],"noncardiac":[50,175,200,292],"irAEs":[51,176,201,293],"in":[52,65,179,264,285],"ICI-treated":[53],"patients.":[54],"METHODS":[55],"We":[56],"conducted":[57],"retrospective":[59],"pooled":[60],"analysis":[61],"MACE":[63,205,303],"captured":[64],"serious":[67],"reporting":[70],"database":[71],"National":[74,81],"Cancer":[75,82],"Institute\u2013Cancer":[76],"Therapy":[77],"Evaluation":[78],"Program":[79],"for":[80,160],"Institute\u2013sponsored":[83],"investigational":[84],"clinical":[85],"trials":[86],"between":[87],"June":[88],"2015":[89],"December":[91],"2019.":[92],"Patients":[93],"were":[94,130,262],"eligible":[95],"if":[96],"they":[97],"had":[98,196,276],"been":[99],"treated":[100,131],"anti\u2013programmed":[102],"cell":[103,107],"death":[104],"protein-1":[105],"(anti\u2013PD-1)/programmed":[106],"death-ligand":[108],"1":[109],"(anti\u2013PD-L1)":[110],"alone":[111],"or":[112,198],"additional":[114],"anticancer":[115,310],"therapies.":[116],"RESULTS":[117],"A":[118],"total":[119,168],"6,925":[121,137],"participants":[122],"received":[123],"anti\u2013PD-(L)1-based":[124,235],"therapies;":[125],"48%":[126],"(n":[127,140,149,162,181,266],"=":[128,141,150,163,182,192,225,244,251,256,267],"3,354)":[129],"single-agent":[133,239],"anti\u2013PD-(L)1":[134,209,215,240,313],"therapy.":[135],"Of":[136],"patients,":[138],"0.6%":[139],"40)":[142,153,166],"qualified":[143],"as":[144],"MACE,":[146],"77.5%":[148],"31":[151],"being":[154],"\u2265":[155],"grade":[156],"3.":[157],"Myocarditis":[158],"accounted":[159],"45%":[161],"18":[164],"ICI-MACEs.":[169],"Concurrent":[170],"multisystem":[171],"involvement":[172],"other":[174],"was":[177,206,228],"seen":[178],"65%":[180],"26":[183],"40).":[185],"Most":[186],"patients":[187,273],"myocarditis":[189,233,261],"(83%,":[190],"n":[191,243,250],"15":[193],"18)":[195],"one":[197],"more":[199],"associated.":[202],"Incidence":[203],"higher":[207,230],"+":[210,216],"targeted":[211],"therapies":[212,237,241,311],"compared":[213],"anti\u2013cytotoxic":[217],"T-cell":[218],"lymphocyte-4":[219],"combinations":[220],"(2.1%":[221],"v":[222,248],"0.9%,":[223],"P":[224,255],".08).":[226,257],"There":[227],"incidence":[231],"combination":[236],"versus":[238],"(0.36%,":[242],"13":[245],"3,571":[247],"0.15%,":[249],"5":[252],"3,354,":[254],"Deaths":[258],"related":[259],"identified":[263],"22.5%":[265],"4":[268],"18).":[270],"All":[271],"four":[272],"who":[274],"died":[275],"concurrent":[277,306],"myositis.":[278],"CONCLUSION":[279],"Increasing":[280],"patient":[281],"prescriber":[283],"awareness":[284],"understanding":[286],"patterns":[287],"ICI-MACE":[289],"associated":[291],"should":[294],"be":[295],"emphasized.":[296],"Better":[297],"characterization":[298],"risk":[301],"use":[307],"non\u2013ICI-based":[309],"treatments":[314],"is":[315],"needed.":[316]},"counts_by_year":[{"year":2026,"cited_by_count":21},{"year":2025,"cited_by_count":21},{"year":2024,"cited_by_count":26},{"year":2023,"cited_by_count":13},{"year":2022,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-06-13T00:00:00"}